nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulfamethoxazole—NAT2—liver cancer	0.527	0.864	CbGaD
Sulfamethoxazole—UGT1A9—Sorafenib—liver cancer	0.13	0.64	CbGbCtD
Sulfamethoxazole—ALB—liver cancer	0.0833	0.136	CbGaD
Sulfamethoxazole—CYP2C8—Sorafenib—liver cancer	0.0313	0.153	CbGbCtD
Sulfamethoxazole—CYP2C9—Sorafenib—liver cancer	0.0218	0.107	CbGbCtD
Sulfamethoxazole—CYP3A4—Sorafenib—liver cancer	0.0127	0.0622	CbGbCtD
Sulfamethoxazole—CYP3A4—Doxorubicin—liver cancer	0.0077	0.0377	CbGbCtD
Sulfamethoxazole—Allergic cutaneous angiitis—Sorafenib—liver cancer	0.00306	0.049	CcSEcCtD
Sulfamethoxazole—Nephrotic syndrome—Sorafenib—liver cancer	0.00201	0.0322	CcSEcCtD
Sulfamethoxazole—Leukocytoclastic vasculitis—Sorafenib—liver cancer	0.00198	0.0318	CcSEcCtD
Sulfamethoxazole—Tubulointerstitial nephritis—Sorafenib—liver cancer	0.00127	0.0204	CcSEcCtD
Sulfamethoxazole—Rhabdomyolysis—Sorafenib—liver cancer	0.0011	0.0176	CcSEcCtD
Sulfamethoxazole—Glossitis—Sorafenib—liver cancer	0.00105	0.0169	CcSEcCtD
Sulfamethoxazole—Anuria—Epirubicin—liver cancer	0.00103	0.0165	CcSEcCtD
Sulfamethoxazole—Anuria—Doxorubicin—liver cancer	0.000951	0.0153	CcSEcCtD
Sulfamethoxazole—Dermatitis exfoliative—Sorafenib—liver cancer	0.000748	0.012	CcSEcCtD
Sulfamethoxazole—Hyponatraemia—Sorafenib—liver cancer	0.000709	0.0114	CcSEcCtD
Sulfamethoxazole—Dapsone—NAT2—liver cancer	0.00067	0.296	CrCbGaD
Sulfamethoxazole—Toxic epidermal necrolysis—Sorafenib—liver cancer	0.000635	0.0102	CcSEcCtD
Sulfamethoxazole—Pancreatitis—Sorafenib—liver cancer	0.000598	0.00959	CcSEcCtD
Sulfamethoxazole—Eruption—Epirubicin—liver cancer	0.000584	0.00936	CcSEcCtD
Sulfamethoxazole—Neutropenia—Sorafenib—liver cancer	0.00057	0.00914	CcSEcCtD
Sulfamethoxazole—Pneumonia—Sorafenib—liver cancer	0.000547	0.00877	CcSEcCtD
Sulfamethoxazole—Infestation NOS—Sorafenib—liver cancer	0.000544	0.00872	CcSEcCtD
Sulfamethoxazole—Infestation—Sorafenib—liver cancer	0.000544	0.00872	CcSEcCtD
Sulfamethoxazole—Eruption—Doxorubicin—liver cancer	0.00054	0.00866	CcSEcCtD
Sulfamethoxazole—Stevens-Johnson syndrome—Sorafenib—liver cancer	0.000539	0.00864	CcSEcCtD
Sulfamethoxazole—Renal failure—Sorafenib—liver cancer	0.000535	0.00857	CcSEcCtD
Sulfamethoxazole—Neuropathy peripheral—Sorafenib—liver cancer	0.000533	0.00855	CcSEcCtD
Sulfamethoxazole—Bone marrow depression—Epirubicin—liver cancer	0.000532	0.00853	CcSEcCtD
Sulfamethoxazole—Stomatitis—Sorafenib—liver cancer	0.00053	0.0085	CcSEcCtD
Sulfamethoxazole—Hepatobiliary disease—Sorafenib—liver cancer	0.000514	0.00825	CcSEcCtD
Sulfamethoxazole—Bone marrow depression—Doxorubicin—liver cancer	0.000492	0.00789	CcSEcCtD
Sulfamethoxazole—Urinary tract disorder—Sorafenib—liver cancer	0.000482	0.00773	CcSEcCtD
Sulfamethoxazole—Neuritis—Epirubicin—liver cancer	0.000481	0.00771	CcSEcCtD
Sulfamethoxazole—Connective tissue disorder—Sorafenib—liver cancer	0.00048	0.00769	CcSEcCtD
Sulfamethoxazole—Urethral disorder—Sorafenib—liver cancer	0.000479	0.00767	CcSEcCtD
Sulfamethoxazole—Erythema multiforme—Sorafenib—liver cancer	0.000462	0.0074	CcSEcCtD
Sulfamethoxazole—Tinnitus—Sorafenib—liver cancer	0.000455	0.0073	CcSEcCtD
Sulfamethoxazole—Neuritis—Doxorubicin—liver cancer	0.000445	0.00714	CcSEcCtD
Sulfamethoxazole—Immune system disorder—Sorafenib—liver cancer	0.000441	0.00707	CcSEcCtD
Sulfamethoxazole—Mediastinal disorder—Sorafenib—liver cancer	0.00044	0.00705	CcSEcCtD
Sulfamethoxazole—Blood disorder—Epirubicin—liver cancer	0.00043	0.0069	CcSEcCtD
Sulfamethoxazole—Mental disorder—Sorafenib—liver cancer	0.000428	0.00686	CcSEcCtD
Sulfamethoxazole—Malnutrition—Sorafenib—liver cancer	0.000425	0.00681	CcSEcCtD
Sulfamethoxazole—Jaundice cholestatic—Epirubicin—liver cancer	0.000409	0.00656	CcSEcCtD
Sulfamethoxazole—Blood disorder—Doxorubicin—liver cancer	0.000398	0.00638	CcSEcCtD
Sulfamethoxazole—Oliguria—Epirubicin—liver cancer	0.00039	0.00625	CcSEcCtD
Sulfamethoxazole—Glossitis—Epirubicin—liver cancer	0.00039	0.00625	CcSEcCtD
Sulfamethoxazole—Angioedema—Sorafenib—liver cancer	0.000388	0.00623	CcSEcCtD
Sulfamethoxazole—Leukopenia—Sorafenib—liver cancer	0.00038	0.0061	CcSEcCtD
Sulfamethoxazole—Jaundice cholestatic—Doxorubicin—liver cancer	0.000378	0.00607	CcSEcCtD
Sulfamethoxazole—Cough—Sorafenib—liver cancer	0.000371	0.00595	CcSEcCtD
Sulfamethoxazole—Myalgia—Sorafenib—liver cancer	0.000362	0.0058	CcSEcCtD
Sulfamethoxazole—Arthralgia—Sorafenib—liver cancer	0.000362	0.0058	CcSEcCtD
Sulfamethoxazole—Glossitis—Doxorubicin—liver cancer	0.000361	0.00578	CcSEcCtD
Sulfamethoxazole—Oliguria—Doxorubicin—liver cancer	0.000361	0.00578	CcSEcCtD
Sulfamethoxazole—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.000359	0.00576	CcSEcCtD
Sulfamethoxazole—Hyperkalaemia—Epirubicin—liver cancer	0.000353	0.00566	CcSEcCtD
Sulfamethoxazole—Anaphylactic shock—Sorafenib—liver cancer	0.000347	0.00556	CcSEcCtD
Sulfamethoxazole—Nervous system disorder—Sorafenib—liver cancer	0.00034	0.00545	CcSEcCtD
Sulfamethoxazole—Thrombocytopenia—Sorafenib—liver cancer	0.00034	0.00544	CcSEcCtD
Sulfamethoxazole—Aplastic anaemia—Epirubicin—liver cancer	0.000337	0.00541	CcSEcCtD
Sulfamethoxazole—Skin disorder—Sorafenib—liver cancer	0.000337	0.0054	CcSEcCtD
Sulfamethoxazole—Anorexia—Sorafenib—liver cancer	0.000331	0.0053	CcSEcCtD
Sulfamethoxazole—Hyperkalaemia—Doxorubicin—liver cancer	0.000327	0.00524	CcSEcCtD
Sulfamethoxazole—Sulfamethazine—ALB—liver cancer	0.000318	0.14	CrCbGaD
Sulfamethoxazole—Sulfadiazine—CYP2E1—liver cancer	0.000318	0.14	CrCbGaD
Sulfamethoxazole—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000316	0.00507	CcSEcCtD
Sulfamethoxazole—Aplastic anaemia—Doxorubicin—liver cancer	0.000312	0.005	CcSEcCtD
Sulfamethoxazole—Sulfamerazine—ALB—liver cancer	0.000311	0.137	CrCbGaD
Sulfamethoxazole—Dyspnoea—Sorafenib—liver cancer	0.000309	0.00496	CcSEcCtD
Sulfamethoxazole—Dyspepsia—Sorafenib—liver cancer	0.000305	0.00489	CcSEcCtD
Sulfamethoxazole—Decreased appetite—Sorafenib—liver cancer	0.000302	0.00483	CcSEcCtD
Sulfamethoxazole—Gastrointestinal disorder—Sorafenib—liver cancer	0.000299	0.0048	CcSEcCtD
Sulfamethoxazole—Fatigue—Sorafenib—liver cancer	0.000299	0.00479	CcSEcCtD
Sulfamethoxazole—Photosensitivity—Epirubicin—liver cancer	0.000297	0.00476	CcSEcCtD
Sulfamethoxazole—Vascular purpura—Epirubicin—liver cancer	0.000292	0.00467	CcSEcCtD
Sulfamethoxazole—Gastrointestinal pain—Sorafenib—liver cancer	0.000284	0.00455	CcSEcCtD
Sulfamethoxazole—Dermatitis exfoliative—Epirubicin—liver cancer	0.000276	0.00443	CcSEcCtD
Sulfamethoxazole—Urticaria—Sorafenib—liver cancer	0.000276	0.00442	CcSEcCtD
Sulfamethoxazole—Photosensitivity—Doxorubicin—liver cancer	0.000275	0.00441	CcSEcCtD
Sulfamethoxazole—Abdominal pain—Sorafenib—liver cancer	0.000274	0.0044	CcSEcCtD
Sulfamethoxazole—Body temperature increased—Sorafenib—liver cancer	0.000274	0.0044	CcSEcCtD
Sulfamethoxazole—Renal impairment—Epirubicin—liver cancer	0.000274	0.00439	CcSEcCtD
Sulfamethoxazole—Purpura—Epirubicin—liver cancer	0.000271	0.00434	CcSEcCtD
Sulfamethoxazole—Vascular purpura—Doxorubicin—liver cancer	0.00027	0.00432	CcSEcCtD
Sulfamethoxazole—Hypoglycaemia—Epirubicin—liver cancer	0.000267	0.00428	CcSEcCtD
Sulfamethoxazole—Hyponatraemia—Epirubicin—liver cancer	0.000262	0.0042	CcSEcCtD
Sulfamethoxazole—Dermatitis exfoliative—Doxorubicin—liver cancer	0.000256	0.0041	CcSEcCtD
Sulfamethoxazole—Hypersensitivity—Sorafenib—liver cancer	0.000256	0.0041	CcSEcCtD
Sulfamethoxazole—Renal impairment—Doxorubicin—liver cancer	0.000254	0.00407	CcSEcCtD
Sulfamethoxazole—Purpura—Doxorubicin—liver cancer	0.00025	0.00401	CcSEcCtD
Sulfamethoxazole—Asthenia—Sorafenib—liver cancer	0.000249	0.00399	CcSEcCtD
Sulfamethoxazole—Hypoglycaemia—Doxorubicin—liver cancer	0.000247	0.00396	CcSEcCtD
Sulfamethoxazole—Pruritus—Sorafenib—liver cancer	0.000245	0.00393	CcSEcCtD
Sulfamethoxazole—Ataxia—Epirubicin—liver cancer	0.000245	0.00393	CcSEcCtD
Sulfamethoxazole—Hyponatraemia—Doxorubicin—liver cancer	0.000242	0.00388	CcSEcCtD
Sulfamethoxazole—Sulfamethizole—ALB—liver cancer	0.000241	0.106	CrCbGaD
Sulfamethoxazole—Diarrhoea—Sorafenib—liver cancer	0.000237	0.0038	CcSEcCtD
Sulfamethoxazole—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.000235	0.00377	CcSEcCtD
Sulfamethoxazole—Dizziness—Sorafenib—liver cancer	0.000229	0.00368	CcSEcCtD
Sulfamethoxazole—Ataxia—Doxorubicin—liver cancer	0.000227	0.00364	CcSEcCtD
Sulfamethoxazole—Eosinophilia—Epirubicin—liver cancer	0.000223	0.00358	CcSEcCtD
Sulfamethoxazole—Pancreatitis—Epirubicin—liver cancer	0.000221	0.00354	CcSEcCtD
Sulfamethoxazole—Vomiting—Sorafenib—liver cancer	0.000221	0.00354	CcSEcCtD
Sulfamethoxazole—Rash—Sorafenib—liver cancer	0.000219	0.00351	CcSEcCtD
Sulfamethoxazole—Dermatitis—Sorafenib—liver cancer	0.000218	0.0035	CcSEcCtD
Sulfamethoxazole—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.000217	0.00348	CcSEcCtD
Sulfamethoxazole—Headache—Sorafenib—liver cancer	0.000217	0.00348	CcSEcCtD
Sulfamethoxazole—Sulfanilamide—CYP2E1—liver cancer	0.000216	0.0953	CrCbGaD
Sulfamethoxazole—Pancytopenia—Epirubicin—liver cancer	0.000214	0.00343	CcSEcCtD
Sulfamethoxazole—Neutropenia—Epirubicin—liver cancer	0.000211	0.00338	CcSEcCtD
Sulfamethoxazole—Eosinophilia—Doxorubicin—liver cancer	0.000207	0.00331	CcSEcCtD
Sulfamethoxazole—Nausea—Sorafenib—liver cancer	0.000206	0.0033	CcSEcCtD
Sulfamethoxazole—Photosensitivity reaction—Epirubicin—liver cancer	0.000206	0.0033	CcSEcCtD
Sulfamethoxazole—Pancreatitis—Doxorubicin—liver cancer	0.000204	0.00328	CcSEcCtD
Sulfamethoxazole—Pneumonia—Epirubicin—liver cancer	0.000202	0.00324	CcSEcCtD
Sulfamethoxazole—Infestation NOS—Epirubicin—liver cancer	0.000201	0.00322	CcSEcCtD
Sulfamethoxazole—Infestation—Epirubicin—liver cancer	0.000201	0.00322	CcSEcCtD
Sulfamethoxazole—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.000199	0.00319	CcSEcCtD
Sulfamethoxazole—Pancytopenia—Doxorubicin—liver cancer	0.000198	0.00318	CcSEcCtD
Sulfamethoxazole—Renal failure—Epirubicin—liver cancer	0.000198	0.00317	CcSEcCtD
Sulfamethoxazole—Neuropathy peripheral—Epirubicin—liver cancer	0.000197	0.00316	CcSEcCtD
Sulfamethoxazole—Stomatitis—Epirubicin—liver cancer	0.000196	0.00314	CcSEcCtD
Sulfamethoxazole—Neutropenia—Doxorubicin—liver cancer	0.000195	0.00313	CcSEcCtD
Sulfamethoxazole—Dapsone—CYP2E1—liver cancer	0.000193	0.085	CrCbGaD
Sulfamethoxazole—Photosensitivity reaction—Doxorubicin—liver cancer	0.00019	0.00305	CcSEcCtD
Sulfamethoxazole—Hepatobiliary disease—Epirubicin—liver cancer	0.00019	0.00305	CcSEcCtD
Sulfamethoxazole—Agranulocytosis—Epirubicin—liver cancer	0.000188	0.00301	CcSEcCtD
Sulfamethoxazole—Pneumonia—Doxorubicin—liver cancer	0.000187	0.003	CcSEcCtD
Sulfamethoxazole—Infestation—Doxorubicin—liver cancer	0.000186	0.00298	CcSEcCtD
Sulfamethoxazole—Infestation NOS—Doxorubicin—liver cancer	0.000186	0.00298	CcSEcCtD
Sulfamethoxazole—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000184	0.00296	CcSEcCtD
Sulfamethoxazole—Renal failure—Doxorubicin—liver cancer	0.000183	0.00293	CcSEcCtD
Sulfamethoxazole—Neuropathy peripheral—Doxorubicin—liver cancer	0.000182	0.00292	CcSEcCtD
Sulfamethoxazole—Stomatitis—Doxorubicin—liver cancer	0.000181	0.00291	CcSEcCtD
Sulfamethoxazole—Hepatitis—Epirubicin—liver cancer	0.00018	0.00289	CcSEcCtD
Sulfamethoxazole—Urinary tract disorder—Epirubicin—liver cancer	0.000178	0.00286	CcSEcCtD
Sulfamethoxazole—Connective tissue disorder—Epirubicin—liver cancer	0.000177	0.00284	CcSEcCtD
Sulfamethoxazole—Urethral disorder—Epirubicin—liver cancer	0.000177	0.00284	CcSEcCtD
Sulfamethoxazole—Hepatobiliary disease—Doxorubicin—liver cancer	0.000176	0.00282	CcSEcCtD
Sulfamethoxazole—Agranulocytosis—Doxorubicin—liver cancer	0.000174	0.00278	CcSEcCtD
Sulfamethoxazole—Erythema multiforme—Epirubicin—liver cancer	0.000171	0.00273	CcSEcCtD
Sulfamethoxazole—Eye disorder—Epirubicin—liver cancer	0.000169	0.0027	CcSEcCtD
Sulfamethoxazole—Tinnitus—Epirubicin—liver cancer	0.000168	0.0027	CcSEcCtD
Sulfamethoxazole—Hepatitis—Doxorubicin—liver cancer	0.000167	0.00268	CcSEcCtD
Sulfamethoxazole—Urinary tract disorder—Doxorubicin—liver cancer	0.000165	0.00264	CcSEcCtD
Sulfamethoxazole—Connective tissue disorder—Doxorubicin—liver cancer	0.000164	0.00263	CcSEcCtD
Sulfamethoxazole—Urethral disorder—Doxorubicin—liver cancer	0.000164	0.00262	CcSEcCtD
Sulfamethoxazole—Immune system disorder—Epirubicin—liver cancer	0.000163	0.00261	CcSEcCtD
Sulfamethoxazole—Mediastinal disorder—Epirubicin—liver cancer	0.000163	0.00261	CcSEcCtD
Sulfamethoxazole—Chills—Epirubicin—liver cancer	0.000162	0.0026	CcSEcCtD
Sulfamethoxazole—Mental disorder—Epirubicin—liver cancer	0.000158	0.00253	CcSEcCtD
Sulfamethoxazole—Erythema multiforme—Doxorubicin—liver cancer	0.000158	0.00253	CcSEcCtD
Sulfamethoxazole—Malnutrition—Epirubicin—liver cancer	0.000157	0.00252	CcSEcCtD
Sulfamethoxazole—Eye disorder—Doxorubicin—liver cancer	0.000156	0.0025	CcSEcCtD
Sulfamethoxazole—Tinnitus—Doxorubicin—liver cancer	0.000156	0.0025	CcSEcCtD
Sulfamethoxazole—Tension—Epirubicin—liver cancer	0.000154	0.00247	CcSEcCtD
Sulfamethoxazole—Nervousness—Epirubicin—liver cancer	0.000153	0.00245	CcSEcCtD
Sulfamethoxazole—Immune system disorder—Doxorubicin—liver cancer	0.000151	0.00242	CcSEcCtD
Sulfamethoxazole—Mediastinal disorder—Doxorubicin—liver cancer	0.00015	0.00241	CcSEcCtD
Sulfamethoxazole—Chills—Doxorubicin—liver cancer	0.00015	0.0024	CcSEcCtD
Sulfamethoxazole—Mental disorder—Doxorubicin—liver cancer	0.000146	0.00234	CcSEcCtD
Sulfamethoxazole—Malnutrition—Doxorubicin—liver cancer	0.000145	0.00233	CcSEcCtD
Sulfamethoxazole—Tension—Doxorubicin—liver cancer	0.000143	0.00229	CcSEcCtD
Sulfamethoxazole—Nervousness—Doxorubicin—liver cancer	0.000141	0.00226	CcSEcCtD
Sulfamethoxazole—Vertigo—Epirubicin—liver cancer	0.000141	0.00226	CcSEcCtD
Sulfamethoxazole—Leukopenia—Epirubicin—liver cancer	0.000141	0.00225	CcSEcCtD
Sulfamethoxazole—Cough—Epirubicin—liver cancer	0.000137	0.0022	CcSEcCtD
Sulfamethoxazole—Convulsion—Epirubicin—liver cancer	0.000136	0.00218	CcSEcCtD
Sulfamethoxazole—Arthralgia—Epirubicin—liver cancer	0.000134	0.00214	CcSEcCtD
Sulfamethoxazole—Myalgia—Epirubicin—liver cancer	0.000134	0.00214	CcSEcCtD
Sulfamethoxazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000133	0.00213	CcSEcCtD
Sulfamethoxazole—Vertigo—Doxorubicin—liver cancer	0.000131	0.00209	CcSEcCtD
Sulfamethoxazole—Leukopenia—Doxorubicin—liver cancer	0.00013	0.00209	CcSEcCtD
Sulfamethoxazole—Anaphylactic shock—Epirubicin—liver cancer	0.000128	0.00205	CcSEcCtD
Sulfamethoxazole—Cough—Doxorubicin—liver cancer	0.000127	0.00203	CcSEcCtD
Sulfamethoxazole—Convulsion—Doxorubicin—liver cancer	0.000126	0.00202	CcSEcCtD
Sulfamethoxazole—Nervous system disorder—Epirubicin—liver cancer	0.000126	0.00202	CcSEcCtD
Sulfamethoxazole—Thrombocytopenia—Epirubicin—liver cancer	0.000126	0.00201	CcSEcCtD
Sulfamethoxazole—Skin disorder—Epirubicin—liver cancer	0.000125	0.002	CcSEcCtD
Sulfamethoxazole—Arthralgia—Doxorubicin—liver cancer	0.000124	0.00198	CcSEcCtD
Sulfamethoxazole—Myalgia—Doxorubicin—liver cancer	0.000124	0.00198	CcSEcCtD
Sulfamethoxazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000123	0.00197	CcSEcCtD
Sulfamethoxazole—Anorexia—Epirubicin—liver cancer	0.000122	0.00196	CcSEcCtD
Sulfamethoxazole—Anaphylactic shock—Doxorubicin—liver cancer	0.000119	0.0019	CcSEcCtD
Sulfamethoxazole—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000117	0.00187	CcSEcCtD
Sulfamethoxazole—Nervous system disorder—Doxorubicin—liver cancer	0.000116	0.00186	CcSEcCtD
Sulfamethoxazole—Thrombocytopenia—Doxorubicin—liver cancer	0.000116	0.00186	CcSEcCtD
Sulfamethoxazole—Insomnia—Epirubicin—liver cancer	0.000116	0.00186	CcSEcCtD
Sulfamethoxazole—Skin disorder—Doxorubicin—liver cancer	0.000115	0.00185	CcSEcCtD
Sulfamethoxazole—Dyspnoea—Epirubicin—liver cancer	0.000114	0.00183	CcSEcCtD
Sulfamethoxazole—Anorexia—Doxorubicin—liver cancer	0.000113	0.00181	CcSEcCtD
Sulfamethoxazole—Dyspepsia—Epirubicin—liver cancer	0.000113	0.00181	CcSEcCtD
Sulfamethoxazole—Decreased appetite—Epirubicin—liver cancer	0.000111	0.00179	CcSEcCtD
Sulfamethoxazole—Gastrointestinal disorder—Epirubicin—liver cancer	0.000111	0.00177	CcSEcCtD
Sulfamethoxazole—Fatigue—Epirubicin—liver cancer	0.000111	0.00177	CcSEcCtD
Sulfamethoxazole—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000108	0.00173	CcSEcCtD
Sulfamethoxazole—Insomnia—Doxorubicin—liver cancer	0.000107	0.00172	CcSEcCtD
Sulfamethoxazole—Dyspnoea—Doxorubicin—liver cancer	0.000106	0.0017	CcSEcCtD
Sulfamethoxazole—Gastrointestinal pain—Epirubicin—liver cancer	0.000105	0.00168	CcSEcCtD
Sulfamethoxazole—Dyspepsia—Doxorubicin—liver cancer	0.000104	0.00167	CcSEcCtD
Sulfamethoxazole—Decreased appetite—Doxorubicin—liver cancer	0.000103	0.00165	CcSEcCtD
Sulfamethoxazole—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000102	0.00164	CcSEcCtD
Sulfamethoxazole—Fatigue—Doxorubicin—liver cancer	0.000102	0.00164	CcSEcCtD
Sulfamethoxazole—Urticaria—Epirubicin—liver cancer	0.000102	0.00163	CcSEcCtD
Sulfamethoxazole—Abdominal pain—Epirubicin—liver cancer	0.000101	0.00162	CcSEcCtD
Sulfamethoxazole—Body temperature increased—Epirubicin—liver cancer	0.000101	0.00162	CcSEcCtD
Sulfamethoxazole—Gastrointestinal pain—Doxorubicin—liver cancer	9.7e-05	0.00155	CcSEcCtD
Sulfamethoxazole—Hypersensitivity—Epirubicin—liver cancer	9.44e-05	0.00151	CcSEcCtD
Sulfamethoxazole—Urticaria—Doxorubicin—liver cancer	9.42e-05	0.00151	CcSEcCtD
Sulfamethoxazole—Abdominal pain—Doxorubicin—liver cancer	9.38e-05	0.0015	CcSEcCtD
Sulfamethoxazole—Body temperature increased—Doxorubicin—liver cancer	9.38e-05	0.0015	CcSEcCtD
Sulfamethoxazole—Asthenia—Epirubicin—liver cancer	9.2e-05	0.00147	CcSEcCtD
Sulfamethoxazole—Pruritus—Epirubicin—liver cancer	9.07e-05	0.00145	CcSEcCtD
Sulfamethoxazole—Diarrhoea—Epirubicin—liver cancer	8.77e-05	0.00141	CcSEcCtD
Sulfamethoxazole—Hypersensitivity—Doxorubicin—liver cancer	8.74e-05	0.0014	CcSEcCtD
Sulfamethoxazole—Asthenia—Doxorubicin—liver cancer	8.51e-05	0.00136	CcSEcCtD
Sulfamethoxazole—Dizziness—Epirubicin—liver cancer	8.48e-05	0.00136	CcSEcCtD
Sulfamethoxazole—Pruritus—Doxorubicin—liver cancer	8.39e-05	0.00135	CcSEcCtD
Sulfamethoxazole—Vomiting—Epirubicin—liver cancer	8.15e-05	0.00131	CcSEcCtD
Sulfamethoxazole—Diarrhoea—Doxorubicin—liver cancer	8.12e-05	0.0013	CcSEcCtD
Sulfamethoxazole—Rash—Epirubicin—liver cancer	8.08e-05	0.0013	CcSEcCtD
Sulfamethoxazole—Dermatitis—Epirubicin—liver cancer	8.07e-05	0.00129	CcSEcCtD
Sulfamethoxazole—Headache—Epirubicin—liver cancer	8.03e-05	0.00129	CcSEcCtD
Sulfamethoxazole—Dizziness—Doxorubicin—liver cancer	7.84e-05	0.00126	CcSEcCtD
Sulfamethoxazole—Nausea—Epirubicin—liver cancer	7.61e-05	0.00122	CcSEcCtD
Sulfamethoxazole—Vomiting—Doxorubicin—liver cancer	7.54e-05	0.00121	CcSEcCtD
Sulfamethoxazole—Rash—Doxorubicin—liver cancer	7.48e-05	0.0012	CcSEcCtD
Sulfamethoxazole—Dermatitis—Doxorubicin—liver cancer	7.47e-05	0.0012	CcSEcCtD
Sulfamethoxazole—Headache—Doxorubicin—liver cancer	7.43e-05	0.00119	CcSEcCtD
Sulfamethoxazole—Nausea—Doxorubicin—liver cancer	7.05e-05	0.00113	CcSEcCtD
Sulfamethoxazole—NAT2—Metabolism—PIK3CB—liver cancer	1.73e-05	0.000143	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—IFNA1—liver cancer	1.73e-05	0.000143	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metapathway biotransformation—GSTM1—liver cancer	1.72e-05	0.000143	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—HPGDS—liver cancer	1.71e-05	0.000142	CbGpPWpGaD
Sulfamethoxazole—ALB—Platelet activation, signaling and aggregation—SERPINE1—liver cancer	1.71e-05	0.000141	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	1.7e-05	0.000141	CbGpPWpGaD
Sulfamethoxazole—ALB—Selenium Micronutrient Network—IL6—liver cancer	1.7e-05	0.000141	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism of lipids and lipoproteins—PPARA—liver cancer	1.68e-05	0.000139	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—TAT—liver cancer	1.67e-05	0.000139	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—ALDOB—liver cancer	1.67e-05	0.000138	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Biological oxidations—CYP1A1—liver cancer	1.66e-05	0.000137	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	1.65e-05	0.000136	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	1.63e-05	0.000135	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—CRABP1—liver cancer	1.6e-05	0.000132	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.55e-05	0.000128	CbGpPWpGaD
Sulfamethoxazole—ALB—Platelet activation, signaling and aggregation—RAF1—liver cancer	1.54e-05	0.000128	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism of lipids and lipoproteins—ALB—liver cancer	1.53e-05	0.000127	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—PRKCE—liver cancer	1.53e-05	0.000126	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—PSMD10—liver cancer	1.53e-05	0.000126	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—PSMA4—liver cancer	1.53e-05	0.000126	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism of lipids and lipoproteins—GGT1—liver cancer	1.51e-05	0.000125	CbGpPWpGaD
Sulfamethoxazole—ALB—Platelet activation, signaling and aggregation—PIK3CB—liver cancer	1.51e-05	0.000125	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism of lipids and lipoproteins—GGT1—liver cancer	1.51e-05	0.000125	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—GOT2—liver cancer	1.48e-05	0.000123	CbGpPWpGaD
Sulfamethoxazole—ALB—Transmembrane transport of small molecules—CYCS—liver cancer	1.46e-05	0.000121	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—ABL1—liver cancer	1.45e-05	0.00012	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—IGF2—liver cancer	1.45e-05	0.00012	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	1.44e-05	0.000119	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—CPT1B—liver cancer	1.4e-05	0.000116	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—GLUL—liver cancer	1.4e-05	0.000116	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—CYP2E1—liver cancer	1.4e-05	0.000115	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—HPGDS—liver cancer	1.4e-05	0.000115	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—CPT1B—liver cancer	1.39e-05	0.000115	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—GLUL—liver cancer	1.39e-05	0.000115	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism of lipids and lipoproteins—PPARG—liver cancer	1.39e-05	0.000115	CbGpPWpGaD
Sulfamethoxazole—ALB—Platelet activation, signaling and aggregation—IL2—liver cancer	1.38e-05	0.000115	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—HGF—liver cancer	1.37e-05	0.000113	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.35e-05	0.000112	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—CSF2—liver cancer	1.35e-05	0.000112	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—NR1H4—liver cancer	1.35e-05	0.000112	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—NR1H4—liver cancer	1.34e-05	0.000111	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—GSTA3—liver cancer	1.33e-05	0.00011	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—GSTA3—liver cancer	1.32e-05	0.000109	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—CYCS—liver cancer	1.31e-05	0.000108	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—GGT1—liver cancer	1.28e-05	0.000106	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—GOT1—liver cancer	1.28e-05	0.000106	CbGpPWpGaD
Sulfamethoxazole—ALB—Transmembrane transport of small molecules—HMOX1—liver cancer	1.27e-05	0.000105	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.26e-05	0.000105	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism of lipids and lipoproteins—ALB—liver cancer	1.25e-05	0.000103	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—PSMA4—liver cancer	1.24e-05	0.000103	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—PSMD10—liver cancer	1.24e-05	0.000103	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—UGDH—liver cancer	1.24e-05	0.000103	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—liver cancer	1.23e-05	0.000102	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—GSTA4—liver cancer	1.21e-05	0.0001	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—GOT2—liver cancer	1.21e-05	0.0001	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—GSTA4—liver cancer	1.21e-05	9.98e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	1.19e-05	9.81e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—GSTA2—liver cancer	1.18e-05	9.78e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	1.18e-05	9.75e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Platelet activation, signaling and aggregation—VEGFA—liver cancer	1.18e-05	9.73e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—GSTA2—liver cancer	1.18e-05	9.72e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—EPT1—liver cancer	1.17e-05	9.64e-05	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—GSTP1—liver cancer	1.15e-05	9.52e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—GSTA1—liver cancer	1.14e-05	9.43e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—CPT1B—liver cancer	1.14e-05	9.42e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—GLUL—liver cancer	1.14e-05	9.42e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—CYP2E1—liver cancer	1.14e-05	9.41e-05	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—HMOX1—liver cancer	1.14e-05	9.39e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—GSTA1—liver cancer	1.13e-05	9.38e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—NAT2—liver cancer	1.13e-05	9.33e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—NAT2—liver cancer	1.12e-05	9.27e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—TAT—liver cancer	1.1e-05	9.14e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.1e-05	9.11e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—NR1H4—liver cancer	1.1e-05	9.08e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—MAPK14—liver cancer	1.09e-05	9.05e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism of lipids and lipoproteins—PPARA—liver cancer	1.08e-05	8.97e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—ALDOB—liver cancer	1.08e-05	8.94e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Platelet activation, signaling and aggregation—TGFB1—liver cancer	1.08e-05	8.93e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—GSTA3—liver cancer	1.08e-05	8.93e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism of lipids and lipoproteins—PPARA—liver cancer	1.08e-05	8.92e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—ALDOB—liver cancer	1.07e-05	8.89e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—CYCS—liver cancer	1.06e-05	8.8e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—F2—liver cancer	1.06e-05	8.77e-05	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—GSTM1—liver cancer	1.06e-05	8.75e-05	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—PIK3CA—liver cancer	1.05e-05	8.72e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—GGT1—liver cancer	1.04e-05	8.64e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—GOT1—liver cancer	1.04e-05	8.64e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—CRABP1—liver cancer	1.03e-05	8.53e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—CRABP1—liver cancer	1.03e-05	8.48e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Transmembrane transport of small molecules—PPARA—liver cancer	1.03e-05	8.48e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—PIK3CG—liver cancer	1.01e-05	8.39e-05	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—CYP1A1—liver cancer	1e-05	8.29e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—GSTA4—liver cancer	9.87e-06	8.17e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	9.65e-06	7.98e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—GSTA2—liver cancer	9.62e-06	7.96e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—GSTP1—liver cancer	9.38e-06	7.76e-05	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—MTHFR—liver cancer	9.35e-06	7.73e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	9.29e-06	7.68e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—GSTA1—liver cancer	9.28e-06	7.68e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—HMOX1—liver cancer	9.25e-06	7.65e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	9.23e-06	7.64e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Platelet activation, signaling and aggregation—PIK3CA—liver cancer	9.19e-06	7.6e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—NAT2—liver cancer	9.18e-06	7.59e-05	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—PPARA—liver cancer	9.17e-06	7.59e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—HPGDS—liver cancer	9.01e-06	7.46e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—HPGDS—liver cancer	8.96e-06	7.41e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—liver cancer	8.96e-06	7.41e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—PIK3CD—liver cancer	8.92e-06	7.37e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism of lipids and lipoproteins—PPARG—liver cancer	8.91e-06	7.37e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—liver cancer	8.82e-06	7.3e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—SERPINE1—liver cancer	8.82e-06	7.29e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—ALDOB—liver cancer	8.8e-06	7.28e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—GSTM1—liver cancer	8.62e-06	7.13e-05	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—AKT1—liver cancer	8.61e-06	7.12e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—CRABP1—liver cancer	8.39e-06	6.94e-05	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	8.24e-06	6.81e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—CYP1A1—liver cancer	8.17e-06	6.76e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	8.16e-06	6.75e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	8.12e-06	6.71e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism of lipids and lipoproteins—ALB—liver cancer	8.06e-06	6.67e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—PSMA4—liver cancer	8.03e-06	6.65e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—PSMD10—liver cancer	8.03e-06	6.65e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—PSMA4—liver cancer	7.99e-06	6.61e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—PSMD10—liver cancer	7.99e-06	6.61e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—RAF1—liver cancer	7.96e-06	6.58e-05	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—PIK3CG—liver cancer	7.85e-06	6.5e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—GOT2—liver cancer	7.82e-06	6.46e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—GOT2—liver cancer	7.77e-06	6.43e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—PIK3CB—liver cancer	7.77e-06	6.43e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—MTHFR—liver cancer	7.62e-06	6.3e-05	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—PPARG—liver cancer	7.58e-06	6.27e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	7.56e-06	6.25e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—CPT1B—liver cancer	7.51e-06	6.21e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—GLUL—liver cancer	7.51e-06	6.21e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Platelet activation, signaling and aggregation—AKT1—liver cancer	7.51e-06	6.21e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—PPARA—liver cancer	7.48e-06	6.18e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—CYP2E1—liver cancer	7.35e-06	6.08e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—HPGDS—liver cancer	7.34e-06	6.07e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—CYP2E1—liver cancer	7.31e-06	6.04e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	7.29e-06	6.03e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—NR1H4—liver cancer	7.24e-06	5.99e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—IL2—liver cancer	7.14e-06	5.9e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—GSTA3—liver cancer	7.12e-06	5.89e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	7.11e-06	5.89e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	7.07e-06	5.85e-05	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—PIK3CD—liver cancer	6.9e-06	5.71e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Transmembrane transport of small molecules—RAF1—liver cancer	6.89e-06	5.7e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—CYCS—liver cancer	6.88e-06	5.69e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—CYCS—liver cancer	6.84e-06	5.65e-05	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—ALB—liver cancer	6.82e-06	5.64e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—GGT1—liver cancer	6.75e-06	5.58e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—GOT1—liver cancer	6.75e-06	5.58e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	6.71e-06	5.55e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—GOT1—liver cancer	6.71e-06	5.55e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—GGT1—liver cancer	6.71e-06	5.55e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	6.64e-06	5.5e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	6.56e-06	5.42e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—PSMA4—liver cancer	6.54e-06	5.41e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—PSMD10—liver cancer	6.54e-06	5.41e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—GSTA4—liver cancer	6.51e-06	5.38e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—PIK3CG—liver cancer	6.4e-06	5.3e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—GOT2—liver cancer	6.36e-06	5.26e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—GSTA2—liver cancer	6.34e-06	5.25e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—PPARG—liver cancer	6.18e-06	5.11e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—GSTA1—liver cancer	6.12e-06	5.06e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—VEGFA—liver cancer	6.06e-06	5.02e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—GSTP1—liver cancer	6.06e-06	5.01e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—NAT2—liver cancer	6.05e-06	5.01e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—GSTP1—liver cancer	6.03e-06	4.98e-05	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—PIK3CB—liver cancer	6.02e-06	4.98e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—CYP2E1—liver cancer	5.98e-06	4.95e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—HMOX1—liver cancer	5.98e-06	4.94e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—HMOX1—liver cancer	5.94e-06	4.92e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—ALDOB—liver cancer	5.8e-06	4.8e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	5.79e-06	4.79e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—PIK3CD—liver cancer	5.63e-06	4.66e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—CYCS—liver cancer	5.6e-06	4.63e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—GSTM1—liver cancer	5.57e-06	4.61e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—TGFB1—liver cancer	5.57e-06	4.6e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—ALB—liver cancer	5.56e-06	4.6e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—GSTM1—liver cancer	5.54e-06	4.58e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—CRABP1—liver cancer	5.54e-06	4.58e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—GOT1—liver cancer	5.49e-06	4.54e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—GGT1—liver cancer	5.49e-06	4.54e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—CYP1A1—liver cancer	5.28e-06	4.37e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—CYP1A1—liver cancer	5.25e-06	4.34e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—KRAS—liver cancer	5.16e-06	4.26e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—GSTP1—liver cancer	4.93e-06	4.08e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—MTHFR—liver cancer	4.92e-06	4.07e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—PIK3CB—liver cancer	4.91e-06	4.06e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—MTHFR—liver cancer	4.89e-06	4.05e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—HMOX1—liver cancer	4.86e-06	4.02e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—HPGDS—liver cancer	4.84e-06	4e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—PPARA—liver cancer	4.83e-06	3.99e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—PPARA—liver cancer	4.8e-06	3.97e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—PIK3CA—liver cancer	4.74e-06	3.92e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—TP53—liver cancer	4.58e-06	3.79e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—GSTM1—liver cancer	4.53e-06	3.75e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—HRAS—liver cancer	4.38e-06	3.63e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	4.34e-06	3.59e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	4.31e-06	3.57e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—PSMD10—liver cancer	4.31e-06	3.57e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—PSMA4—liver cancer	4.31e-06	3.57e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—CYP1A1—liver cancer	4.3e-06	3.55e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—GOT2—liver cancer	4.2e-06	3.47e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—PIK3CG—liver cancer	4.14e-06	3.42e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—PIK3CG—liver cancer	4.11e-06	3.4e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—MTHFR—liver cancer	4.01e-06	3.31e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—PPARG—liver cancer	3.99e-06	3.3e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—PPARG—liver cancer	3.97e-06	3.28e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—CYP2E1—liver cancer	3.94e-06	3.26e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—PPARA—liver cancer	3.93e-06	3.25e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—AKT1—liver cancer	3.87e-06	3.2e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—CYCS—liver cancer	3.69e-06	3.05e-05	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—PIK3CA—liver cancer	3.67e-06	3.03e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—PIK3CD—liver cancer	3.64e-06	3.01e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—GGT1—liver cancer	3.62e-06	3e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—GOT1—liver cancer	3.62e-06	3e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—PIK3CD—liver cancer	3.61e-06	2.99e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—ALB—liver cancer	3.59e-06	2.97e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.53e-06	2.92e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—PIK3CG—liver cancer	3.37e-06	2.78e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—GSTP1—liver cancer	3.25e-06	2.69e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—PPARG—liver cancer	3.25e-06	2.69e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—HMOX1—liver cancer	3.21e-06	2.65e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—PIK3CB—liver cancer	3.17e-06	2.62e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—PIK3CB—liver cancer	3.15e-06	2.61e-05	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—AKT1—liver cancer	3e-06	2.48e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—PIK3CA—liver cancer	2.99e-06	2.47e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—GSTM1—liver cancer	2.99e-06	2.47e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—PIK3CD—liver cancer	2.96e-06	2.45e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—ALB—liver cancer	2.92e-06	2.42e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—CYP1A1—liver cancer	2.83e-06	2.34e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—MTHFR—liver cancer	2.64e-06	2.19e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—PPARA—liver cancer	2.59e-06	2.14e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—PIK3CB—liver cancer	2.58e-06	2.13e-05	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—AKT1—liver cancer	2.44e-06	2.02e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—PIK3CG—liver cancer	2.22e-06	1.84e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—PPARG—liver cancer	2.14e-06	1.77e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—PIK3CD—liver cancer	1.95e-06	1.61e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—PIK3CA—liver cancer	1.93e-06	1.6e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—ALB—liver cancer	1.93e-06	1.59e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—PIK3CA—liver cancer	1.92e-06	1.59e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—PIK3CB—liver cancer	1.7e-06	1.41e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—AKT1—liver cancer	1.58e-06	1.31e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—PIK3CA—liver cancer	1.57e-06	1.3e-05	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—AKT1—liver cancer	1.57e-06	1.3e-05	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—AKT1—liver cancer	1.28e-06	1.06e-05	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—PIK3CA—liver cancer	1.04e-06	8.58e-06	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—AKT1—liver cancer	8.47e-07	7.01e-06	CbGpPWpGaD
